{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-26-000036","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.985561+00:00","generated_at":"2026-05-15T08:11:42.961116+00:00","sec_items":["2.03","1.01","7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Denali Therapeutics receives $200M from Royalty Pharma after FDA approval of tividenofusp alfa","bullets":["Received $200.0M gross proceeds from Royalty Pharma under synthetic royalty funding agreement.","Closing followed FDA accelerated approval of tividenofusp alfa on March 24, 2026.","Synthetic royalty agreement was previously announced on December 4, 2025.","Proceeds provide non-dilutive capital for further development and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-26-000036","json":"https://secwatch.observer/filing/0001714899-26-000036.json","markdown":"https://secwatch.observer/filing/0001714899-26-000036.md","text":"https://secwatch.observer/filing/0001714899-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000036/0001714899-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000036/dnli-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:11:42.961116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}